Division of Nestle SA/Alcon Inc./EsbaTech AG
Latest From Alcon Inc.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.
The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Nestle SA
- Novartis AG
- Senior Management
David Endicott, CEO
Timothy C Stonesifer, SVP, CFO
Franck Leveiller, Head, Global R&D
Laurent Attias, SVP, Corp. Dev. Strategy
Ed McGough, SVP, Global Mfctng. & Technical Operations
- Contact Info
Phone: (41)(800) 862-5266
6201 South Freeway
Fort Worth, TX 76134-2001
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.